Your browser doesn't support javascript.
loading
A Chemoenzymatic Approach To Produce a Cyclic Analogue of the Analgesic Drug MVIIA (Ziconotide).
Zhou, Yan; Harvey, Peta J; Koehbach, Johannes; Chan, Lai Yue; Jones, Alun; Andersson, Åsa; Vetter, Irina; Durek, Thomas; Craik, David J.
Afiliação
  • Zhou Y; ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Harvey PJ; ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Koehbach J; ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Chan LY; ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Jones A; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Andersson Å; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Vetter I; School of Pharmacy, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Durek T; ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
  • Craik DJ; ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.
Angew Chem Int Ed Engl ; 62(29): e202302812, 2023 07 17.
Article em En | MEDLINE | ID: mdl-37148162
ABSTRACT
Ziconotide (ω-conotoxin MVIIA) is an approved analgesic for the treatment of chronic pain. However, the need for intrathecal administration and adverse effects have limited its widespread application. Backbone cyclization is one way to improve the pharmaceutical properties of conopeptides, but so far chemical synthesis alone has been unable to produce correctly folded and backbone cyclic analogues of MVIIA. In this study, an asparaginyl endopeptidase (AEP)-mediated cyclization was used to generate backbone cyclic analogues of MVIIA for the first time. Cyclization using six- to nine-residue linkers did not perturb the overall structure of MVIIA, and the cyclic analogues of MVIIA showed inhibition of voltage-gated calcium channels (CaV 2.2) and substantially improved stability in human serum and stimulated intestinal fluid. Our study reveals that AEP transpeptidases are capable of cyclizing structurally complex peptides that chemical synthesis cannot achieve and paves the way for further improving the therapeutic value of conotoxins.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Conotoxinas / ômega-Conotoxinas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Conotoxinas / ômega-Conotoxinas Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article